*July 2025* Osimertinib's approval for NSCLC post chemoradiation is supported by the LAURA trial, showing improved overall survival compared with placebo. The ORCHARD study is evaluating osimertinib with datopotamab deruxtecan, demonstrating promising progression-free survival and response rates in EGFR-mutated NSCLC. The MARIPOSA trial showed that amivantamab plus lazertinib offers an…

*September 2025* Key Takeaways Iza-bren plus osimertinib achieved a 100% objective response rate in EGFR-mutated NSCLC, with a confirmed ORR of 95% at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92.1% and 94.8%, respectively, indicating strong efficacy. The treatment was well-tolerated, with hematologic adverse…

*September 2025* Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, joined Lung Cancers Today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) to discuss an update on the HARMONi study. Note to reader: This drug…

*September 2025* At the WCLC 2025 Presidential Symposium Dr. David Planchard presented the Overall Survival (OS) results from the FLAURA2 trial. This pivotal study demonstrated that adding chemotherapy to Osimertinib significantly improves survival outcomes in first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC), marking a major advancement in…

*September 2025* A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study showed that continuing osimertinib with the addition…

*September 2025* Key Takeaways Iza-bren targets EGFR and HER3, showing potential in treating EGFR-mutant NSCLC after progression on EGFR TKI and platinum-based chemotherapy. The FDA's breakthrough therapy designation highlights iza-bren's potential to improve clinical outcomes for previously treated EGFR-mutated NSCLC patients. Clinical trials focus on determining the recommended phase 2…

Here are a collection of webinars from the American Cancer Society Roundtable on various topics of lung cancer: staging, treatments, radiation, surgery, advocacy, etc. View those that are of interest to you. View webinars here.